company background image
IDGX

Integrated Diagnostics Holdings OTCPK:IDGX.F Stock Report

Last Price

US$0.68

Market Cap

US$540.0m

7D

0%

1Y

-25.2%

Updated

05 Aug, 2022

Data

Company Financials +
IDGX.F fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance6/6
Financial Health5/6
Dividends3/6

IDGX.F Stock Overview

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients.

Integrated Diagnostics Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Integrated Diagnostics Holdings
Historical stock prices
Current Share PriceUS$0.68
52 Week HighUS$1.50
52 Week LowUS$0.65
Beta0.69
1 Month Change-10.46%
3 Month Change-37.91%
1 Year Change-25.22%
3 Year Change-44.45%
5 Year Changen/a
Change since IPO-44.08%

Recent News & Updates

Shareholder Returns

IDGX.FUS HealthcareUS Market
7D0%0.6%1.0%
1Y-25.2%12.6%-12.8%

Return vs Industry: IDGX.F underperformed the US Healthcare industry which returned 12.5% over the past year.

Return vs Market: IDGX.F underperformed the US Market which returned -12.7% over the past year.

Price Volatility

Is IDGX.F's price volatile compared to industry and market?
IDGX.F volatility
IDGX.F Average Weekly Movementn/a
Healthcare Industry Average Movement9.6%
Market Average Movement8.1%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market3.2%

Stable Share Price: Insufficient data to determine IDGX.F's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine IDGX.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19796,388Hend El Sherbinihttps://www.idhcorp.com

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 2,000 diagnostic test services, including immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. The company operates in Egypt, Jordan, Sudan, and Nigeria.

Integrated Diagnostics Holdings Fundamentals Summary

How do Integrated Diagnostics Holdings's earnings and revenue compare to its market cap?
IDGX.F fundamental statistics
Market Capج.م10.33b
Earnings (TTM)ج.م1.38b
Revenue (TTM)ج.م5.28b

7.5x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IDGX.F income statement (TTM)
Revenueج.م5.28b
Cost of Revenueج.م2.58b
Gross Profitج.م2.70b
Other Expensesج.م1.31b
Earningsج.م1.38b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.31
Gross Margin51.13%
Net Profit Margin26.22%
Debt/Equity Ratio3.3%

How did IDGX.F perform over the long term?

See historical performance and comparison

Dividends

12.7%

Current Dividend Yield

94%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is IDGX.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDGX.F?

Other financial metrics that can be useful for relative valuation.

IDGX.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.7x
Enterprise Value/EBITDA3.9x
PEG Ratio0.5x

Price to Earnings Ratio vs Peers

How does IDGX.F's PE Ratio compare to its peers?

IDGX.F PE Ratio vs Peers
The above table shows the PE ratio for IDGX.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average19.5x
INNV InnovAge Holding
46.8x84.2%US$592.2m
CCRN Cross Country Healthcare
4.3x-33.2%US$924.4m
CO Global Cord Blood
4.1xn/aUS$303.9m
DCGO DocGo
24.4x24.9%US$879.9m
IDGX.F Integrated Diagnostics Holdings
7.5x15.4%US$540.0m

Price-To-Earnings vs Peers: IDGX.F is good value based on its Price-To-Earnings Ratio (7.5x) compared to the peer average (19.5x).


Price to Earnings Ratio vs Industry

How does IDGX.F's PE Ratio compare vs other companies in the US Healthcare Industry?

Price-To-Earnings vs Industry: IDGX.F is good value based on its Price-To-Earnings Ratio (7.5x) compared to the US Healthcare industry average (19.5x)


Price to Earnings Ratio vs Fair Ratio

What is IDGX.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDGX.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate IDGX.F's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of IDGX.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IDGX.F ($0.68) is trading below our estimate of fair value ($2.49)

Significantly Below Fair Value: IDGX.F is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Integrated Diagnostics Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDGX.F's forecast earnings growth (15.4% per year) is above the savings rate (1.9%).

Earnings vs Market: IDGX.F's earnings (15.4% per year) are forecast to grow faster than the US market (12.8% per year).

High Growth Earnings: IDGX.F's earnings are forecast to grow, but not significantly.

Revenue vs Market: IDGX.F's revenue (10.9% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: IDGX.F's revenue (10.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IDGX.F's Return on Equity is forecast to be very high in 3 years time (60%).


Discover growth companies

Past Performance

How has Integrated Diagnostics Holdings performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


30.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IDGX.F has high quality earnings.

Growing Profit Margin: IDGX.F's current net profit margins (26.2%) are higher than last year (24.8%).


Past Earnings Growth Analysis

Earnings Trend: IDGX.F's earnings have grown significantly by 30.8% per year over the past 5 years.

Accelerating Growth: IDGX.F's earnings growth over the past year (69.5%) exceeds its 5-year average (30.8% per year).

Earnings vs Industry: IDGX.F earnings growth over the past year (69.5%) exceeded the Healthcare industry 9.5%.


Return on Equity

High ROE: IDGX.F's Return on Equity (48.6%) is considered outstanding.


Discover strong past performing companies

Financial Health

How is Integrated Diagnostics Holdings's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: IDGX.F's short term assets (EGP3.4B) exceed its short term liabilities (EGP2.5B).

Long Term Liabilities: IDGX.F's short term assets (EGP3.4B) exceed its long term liabilities (EGP1.2B).


Debt to Equity History and Analysis

Debt Level: IDGX.F has more cash than its total debt.

Reducing Debt: IDGX.F's debt to equity ratio has increased from 2.5% to 3.3% over the past 5 years.

Debt Coverage: IDGX.F's debt is well covered by operating cash flow (2132.5%).

Interest Coverage: IDGX.F earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Integrated Diagnostics Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


12.74%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: IDGX.F's dividend (12.74%) is higher than the bottom 25% of dividend payers in the US market (1.53%).

High Dividend: IDGX.F's dividend (12.74%) is in the top 25% of dividend payers in the US market (4.1%)


Stability and Growth of Payments

Stable Dividend: IDGX.F has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: IDGX.F's dividend payments have increased, but the company has only paid a dividend for 6 years.


Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (94.1%), IDGX.F's dividend payments are not well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (72.2%), IDGX.F's dividend payments are covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.6yrs

Average board tenure


CEO

Hend El Sherbini (53 yo)

10.58yrs

Tenure

ج.م8,945,102

Compensation

Prof. Dr. Hend El Sherbini has been Group Chief Executive Officer of Integrated Diagnostics Holdings plc since 2012 and as its Executive Director since December 23, 2014. Prof. Dr. El Sherbini serves as th...


CEO Compensation Analysis

Compensation vs Market: Hend's total compensation ($USD467.51K) is below average for companies of similar size in the US market ($USD2.70M).

Compensation vs Earnings: Hend's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: IDGX.F's board of directors are considered experienced (7.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Integrated Diagnostics Holdings plc's employee growth, exchange listings and data sources


Key Information

  • Name: Integrated Diagnostics Holdings plc
  • Ticker: IDGX.F
  • Exchange: OTCPK
  • Founded: 1979
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$540.000m
  • Shares outstanding: 600.00m
  • Website: https://www.idhcorp.com

Number of Employees


Location

  • Integrated Diagnostics Holdings plc
  • 12 Castle Street
  • Saint Helier
  • JE2 3RT
  • Jersey

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/05 00:00
End of Day Share Price2022/07/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.